Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Hedeker Wealth LLC

Hedeker Wealth LLC increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 1.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 76,203 shares of the company’s stock after purchasing an additional 916 shares during the quarter. Hedeker Wealth LLC owned 0.13% of Harmony Biosciences worth $2,622,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC grew its position in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares in the last quarter. Mendota Financial Group LLC grew its position in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after acquiring an additional 965 shares during the period. CWM LLC grew its stake in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after buying an additional 775 shares in the last quarter. KBC Group NV grew its stake in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after buying an additional 819 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Harmony Biosciences in the third quarter valued at $74,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Raymond James reaffirmed an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Harmony Biosciences in a report on Monday, January 27th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Monday, January 13th. Finally, Mizuho boosted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $38.78 on Friday. The stock has a market capitalization of $2.21 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61. The stock’s 50-day moving average price is $35.66 and its 200 day moving average price is $35.42. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sandip Kapadia sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock worth $2,831,679 in the last quarter. Company insiders own 30.80% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.